K-V Pharmaceutical is protesting drug maker Hologic Inc.'s "brazen" attempt to circumvent bankruptcy law to get its hands on the rights to Makena, a drug that reduces the risk of premature births ...

At the beginning, the vote found that 46% of the 400-odd audience agreed that “pharma is getting its act together”. Approximately 69% believed that all clinical trial results should be ...

K-V Pharmaceutical Co. Monday unveiled a bankruptcy-exit plan that hinges on a $20 million rights offering and has already earned the support of a group of senior noteholders.

HYDERABAD, India -- The death toll from Monday's massive explosion and fire at a pharmaceutical factory in India’s southern ...

Hyderabad: Aurobindo Pharma Limited has announced the merger of its two wholly owned step-down subsidiaries - Pharmacin B.V.

K-V Pharmaceutical Announces Updated Makena® Performance Metrics--Fiscal 2012 Second Quarter Form 10-Q Delayed due to Restatement of Prior Financial Statements; Restatement has No Impact on Cash ...

Following K-V Pharma’s recent filing for bankruptcy, Daniel Ghinn takes a look at the part social media played and shares his thoughts on just how important it is for pharma companies to have a ...

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) declared in 2024 that three Phase 3 trials of its main drugs had yielded positive topline outcomes. With a fixed-dose combination, ...

Fintel reports that on June 17, 2025, Citigroup initiated coverage of NewAmsterdam Pharma Company N.V. (NasdaqGM:NAMS) with a Buy recommendation. Analyst Price Forecast Suggests 126.67% Upside As of ...

K-V PHARMACEUTICAL COMMENTS ON ACOG AND SMFM INFORMATION UPDATE REGARDING HYDROXYPROGESTERONE CAPROATE - FDA-APPROVED MAKENA TM AND COMPOUNDED 17P St. Louis, MO - October 13, 2011 - K-V ...

CHAPTER 11: K-V Pharmaceutical Co. filed for Chapter 11 bankruptcy protection Saturday, saying weak sales of its preterm birth drug Makena and regulatory sanctions are hurting its business ...

The Supreme Court's Decision on whether pharma sales reps should qualify for the 'outside sales exemption' could have far reaching implications, write Lisa A. Schreter and Kimberly J. Gost. The ...